WEBULL
WebtradeDownload

Liquidia (LQDA) Could Be 71% Undervalued On Patent Ruling Risk

Simply Wall St · 2d ago

Liquidia (LQDA) is back in focus after a U.S. District Court ruled that key claims of a United Therapeutics patent are valid and infringed by YUTREPIA, leaving potential remedies and market access questions open.

The latest court decision arrives after a sharp reset in Liquidia’s 30 day share price return, which is down 58.6%, and a 90 day share price return that is lower by 64.0%. This comes even as the 1 year total shareholder return is 15.6% and the 5 year total shareholder return is roughly 7.6x, suggesting long term holders are still sitting on very large gains despite recent pressure linked to changing expectations around YUTREPIA’s risk profile.

Spot under-pressure biopharma plays facing similar legal or product risks by scanning our hand picked 20 high quality undiscovered gems alongside Liquidia today.

The bull case argues that Liquidia’s pullback misprices YUTREPIA’s long term potential, while the bear view sees permanent damage to that thesis. Which side do the current valuation markers support next?

Most Popular Narrative: 71% Undervalued

Against Liquidia’s last close of $28.02, the most widely followed narrative pins fair value at $98.13. This frames the recent selloff as a big valuation gap that hinges on how much of the treprostinil market YUTREPIA and follow on assets can eventually support.

Planned expansion of North Carolina manufacturing capacity, with a new facility targeted to potentially triple production capability by 2026, positions Liquidia to meet higher volume needs for YUTREPIA and future products such as L606.

This can support scaling benefits across cost of goods, operating margins and long term earnings power if demand materializes.

See why 5 investors see Liquidia as 71% undervalued.

Result: Fair Value of $98.13 (UNDERVALUED)

Still, the narrative around Liquidia can break if court ordered remedies restrict YUTREPIA’s market access, or if demand fails to justify expanded manufacturing capacity.

Find out about the key risks to this Liquidia narrative.

Next Steps

If the mixed sentiment on Liquidia leaves you torn, step off the sidelines and review the data on both risks and rewards directly. Then use the 3 key rewards and 2 important warning signs.

Looking for more Liquidia investment ideas beyond this story?

Do not stop your research with Liquidia alone. Put fresh possibilities on your radar by running a quick sweep through focused stock lists that match your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.